CVC Capital Partners Fund VII announced that it had entered into exclusive negotiations with Charterhouse Capital Partners for the acquisition of a majority stake in Cooper.
On March 12, Willkie client CVC Capital Partners, through its CVC Capital Partners Fund VII, announced that it had entered into exclusive negotiations with Charterhouse Capital Partners for the acquisition of a majority stake in Cooper Consumer Health (Cooper).
Cooper is a leading European independent over-the-counter (OTC) drug manufacturer and distributor. Cooper was acquired by Charterhouse in 2016 and revenues are now close to €500 million.
Charterhouse would make a significant reinvestment in Cooper and continue to support the growth and international expansion of the business alongside CVC, which has partnered with Vemedia founder Yvan Vindevogel and specialized healthcare fund Avista Capital Partners, and the management team.
The transaction is subject to workers’ council information and consultation and to the approval of relevant regulatory authorities.
The Willkie deal team was led by partner Cédric Hajage and included partner Grégoire Finance and counsel Hugo Nocerino with partner Sebastian FitzGerald leading on the financing aspects with associates Tim Sawyer and Chloe Szczerbiak.